Clinical trials: Metastatic Clear-cell Renal Cancer
Metastatic Renal Cell Carcinoma
Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
This was a Phase I/II, single-center, dose-escalation study. 177-Lutetium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-cG250 (177-Lu-DOTA-cG250) was administered at a starting dose of 30 mCi/m^2 of 177-Lu (fixed dose…
- Trial name
- NCT00142415
- Testing
- 111-In-DOTA-cG250, 177-Lu-DOTA-cG250
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Ludwig Institute for Cancer Research
Clear Cell Renal Cell Carcinoma
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
The main purpose of this study is to find out how useful dovitinib is when given as the initial treatment to participants with advanced kidney cancer, that has spread to other parts of the body.
- Trial name
- DILIGENCE-1 (NCT01791387)
- Testing
- Dovitinib
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Auckland District Health Board
Advanced Non-clear Cell Renal Cell Carcinoma
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
- Trial name
- ASPEN (NCT01108445)
- Testing
- Everolimus, Sunitinib
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 131 people
- Sponsor
- Duke University
Clear Cell Renal Cell Carcinoma
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
This study will evaluate the use of nivolumab before surgery in patients with high-risk clear cell renal cell carcinoma who are eligible for nephrectomy.
- Trial name
- NCT02575222
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Patients with advanced renal cell carcinoma (RCC) are classified according to Memorial Sloan-Kettering Cancer Center (MSKCC) criteria in three risk-groups: favourable, intermediate and poor.
- Conditions
- Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
- Trial name
- FLIPPER (NCT01521715)
- Testing
- Pazopanib
- Where
- 8 sites in Germany
- Volunteers
- 44 people
- Sponsor
- iOMEDICO AG
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC)
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or…
- Conditions
- Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
- Trial name
- NCT07188896
- Testing
- Fianlimab, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Brian Rini
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial studies different combinations of bevacizumab, temsirolimus, and sorafenib tosylate to see how well they work compared with bevacizumab alone in treating patients with kidney cancer that has spread…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT00378703
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 559 sites in United States, Peru
- Volunteers
- 361 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion
This is a prospective, single-center, single-arm phase 2 study in patients with clear cell renal cell carcinoma and metastasis or recurrence suspicion.
- Trial name
- NCT05879497
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer
Immunotherapy Study for Metastatic Renal Cell Cancer
In this Phase 1 Trial investigators plan to establish the MTD of HyperAcute®-Renal (HAR) immunotherapy in subjects with clinically metastatic renal cell carcinoma.
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Clear-cell Renal Cancer, Recurrent Renal Cell Carcinoma, Refractory Renal Cell Carcinoma
- Trial name
- NCT02035358
- Testing
- HyperAcute®-Renal (HAR) Immunotherapy
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- NewLink Genetics Corporation
Renal Cell Cancer Metastatic
Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
The SOGUG-TIVOREAL study is a retrospective observational study with medications. This study is based on the retrospective collection of data from patients who have been treated with Tivozanib as first-line therapy between…
- Trial name
- SOGUG-TIVOREAL (NCT07354282)
- Where
- 14 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC.
- Conditions
- Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer
- Trial name
- NCT03634540
- Testing
- Belzutifan, Cabozantinib
- Where
- 10 sites in United States
- Volunteers
- 118 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Kidney Cancer
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00301990
- Testing
- aldesleukin, bevacizumab
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.
- Conditions
- Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy, Clear Cell Renal Cell Cancer (ccRCC)
- Trial name
- NCT06279403
- Testing
- Toripalimab, Cytoreductive Nephrectomy, Axitinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- RenJi Hospital
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease.
- Trial name
- NCT05745142
- Testing
- Sunitinib
- Where
- Turkey (Türkiye)
- Volunteers
- 376 people
- Sponsor
- Pfizer
Kidney Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027573
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib…
- Trial name
- CANTATA (NCT03428217)
- Testing
- CB-839, Cabozantinib
- Where
- 133 sites in United States, Australia and 6 more
- Volunteers
- 444 people
- Sponsor
- Calithera Biosciences, Inc
Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and…
- Conditions
- Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid Tumor
- Trial name
- NCT05263050
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fox Chase Cancer Center
Renal Cell Carcinoma
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or…
- Trial name
- NCT07195682
- Testing
- BMS-986506, Pumitamig, Ipilimumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
The purpose of this study is to see how well the study drug, axitinib, helps control renal (kidney) cancer that has come back (recurrent) or spread (metastatic).
- Trial name
- PrE0801 (NCT01649180)
- Testing
- Axitinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- PrECOG, LLC.
Clear Cell RCC
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
This is an open label, single-centre phase 1/2 study involving a single dose of Temferon, an investigational Advanced Therapy Medicinal Product (ATMP), to treat patients with metastatic clear cell renal cell carcinoma (RCC) with…
- Trial name
- TEM-GU (NCT06716853)
- Testing
- Temferon, Pembrolizumab, Cabozantinib
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Genenta Science